I like the use of proceeds section
We estimate that the net proceeds to us from this offering, after deducting the estimated offering expenses payable by us, will be approximately $ million, excluding any proceeds we may receive upon exercise of the warrants, if any. We intend to use the net proceeds of this offering for the commercial launch of FlutiCare™, if approved by the FDA, working capital and general corporate purposes, including sales and marketing activities, product development, capital expenditures, the potential repayment of certain debt of the Company and product acquisitions and product licenses. See “ Use of Proceeds ” for a more complete description of the intended use of proceeds from this offering.
Sounds encouraging but we will see
